Determinants of cancer response to immunotherapy

Abstract

Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy.

1 .- 10 . (canceled) 
     
     
         11 . A method of treating cancer, the method comprising a step of:
 administering to a subject suffering from or susceptible to a cancer and determined to carry a serpin mutation a composition comprising a neoepitope.   
     
     
         12 . The method of  claim 11 , wherein the serpin mutation is or comprises a mutation listed in Table 1. 
     
     
         13 . The method of  claim 11 , wherein the composition comprising a neoepitope is an immunogenic peptide. 
     
     
         14 . The method of  claim 13 , wherein the immunogenic peptide is one listed in Table 4 or Table 5. 
     
     
         15 . The method of  claim 11 , wherein the neoepitope has been detected in a sample from the subject. 
     
     
         16 . The method of  claim 15 , wherein the sample is or comprises ctDNA. 
     
     
         17 . The method of  claim 15 , wherein the sample is or comprises tissue. 
     
     
         18 . The method of  claim 15 , wherein the neoepitope has been detected by exome sequencing or by qPCR. 
     
     
         19 . (canceled) 
     
     
         20 . The method of  claim 11 , wherein the patient has received or is receiving one or more other therapeutic agents.